The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Annals of Clinical and Translational Neurology2018Vol. 5(12), pp. 1460–1477
Citations Over TimeTop 1% of 2018 papers
Kenneth Marek, Sohini Chowdhury, Andrew Siderowf, Shirley Lasch, Christopher S. Coffey, Chelsea Caspell‐Garcia, Tanya Simuni, Danna Jennings, Caroline M. Tanner, John Q. Trojanowski, Leslie M. Shaw, John Seibyl, Norbert Schuff, Andrew Singleton, Karl Kieburtz, Arthur W. Toga, Brit Mollenhauer, Doug Galasko, Lana M. Chahine, Daniel Weintraub, Tatiana Foroud, Duygu Tosun, Kathleen L. Poston, Vanessa Arnedo, Mark Frasier, Todd Sherer, the Parkinson's Progression Markers Initiative
Abstract
PPMI has detailed the biomarker signature for an early PD cohort defined by clinical features and imaging biomarkers. This strategy provides the framework to establish biomarker cohorts and to define longitudinal progression biomarkers to support future PD treatment trials.
Related Papers
- → [ 11 C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease(1997)172 cited
- → Dopamine transporter levels in cocaine dependent subjects(2008)52 cited
- → Recovery of dopaminergic system after cocaine exposure and impact of a long‐acting cocaine hydrolase(2022)9 cited
- PET Imaging of Dopamine Transporter(DAT) in the Diagnosis of Parkinson's Disease(2008)
- Assessing brain dopamine system by dopamine transporter ligand ~(18)F-FP-CIT with positron emission tomography(2004)